Related Articles
Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer
Effect of dutasteride on castration‑resistant prostate cancer
Clinical predictor of survival following docetaxel‑based chemotherapy
Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer
Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate